Stephane BancelFiled
- MRNAModerna, Inc.Chief Executive Officerfiled Aug 7, 2026
Monthly open-market value · 24 months Filed
- Bought (open market)
- Sold (open market)
Unusual activity Estimated
- 65Insider overlapAug 19, 2026
Rep. Maria Elvira Salazar bought MRNA 14 days after its CEO sold $11M
Details
- Politician
- Maria Elvira Salazar
- Ticker
- MRNA
- Asset
- Moderna, Inc. - Common Stock (MRNA)
- Tx type
- buy
- Tx date
- Aug 19, 2026
- Filing date
- Sep 9, 2026
- Amount low
- $1,001
- Amount high
- $15,000
- Amount mid
- $8,001
- Disclosed range
- $1,001 - $15,000
- Reporting lag days
- 21
- Is whale
- No
- Insider trade
- {"insider":{"slug":"stephane-bancel","name":"Stephane Bancel","title":"Chief Executive Officer","short_title":"CEO"},"company":"Moderna, Inc.","ticker":"MRNA","tx_kind":"open_market_sale","tx_date":"2026-08-05","shares":187044,"price":58.79,"value":10996316.76,"is_10b5_1":true}
- Days between
- 14
- Opposite side
- Yes
- 50Insider overlapAug 19, 2026
Rep. Maria Elvira Salazar partially sold MRNA 14 days after its CEO sold $11M
Details
- Politician
- Maria Elvira Salazar
- Ticker
- MRNA
- Asset
- Moderna, Inc. - Common Stock (MRNA)
- Tx type
- partial_sale
- Tx date
- Aug 19, 2026
- Filing date
- Sep 9, 2026
- Amount low
- $1,001
- Amount high
- $15,000
- Amount mid
- $8,001
- Disclosed range
- $1,001 - $15,000
- Reporting lag days
- 21
- Is whale
- No
- Insider trade
- {"insider":{"slug":"stephane-bancel","name":"Stephane Bancel","title":"Chief Executive Officer","short_title":"CEO"},"company":"Moderna, Inc.","ticker":"MRNA","tx_kind":"open_market_sale","tx_date":"2026-08-05","shares":187044,"price":58.79,"value":10996316.76,"is_10b5_1":true}
- Days between
- 14
- Opposite side
- No
- 30Exec saleAug 5, 2026
MRNA CEO Stephane Bancel sold $11M (10b5-1 plan)
Details
- Insider
- Stephane Bancel
- Company
- Moderna, Inc.
- Ticker
- MRNA
- Tx kind
- open_market_sale
- Tx date
- Aug 5, 2026
- Shares
- 187,044
- Price
- $59
- Value
- $11M
- Is 10b5 1
- Yes
- 28Exec saleAug 5, 2026
MRNA CEO Stephane Bancel sold $8.3M (10b5-1 plan)
Details
- Insider
- Stephane Bancel
- Company
- Moderna, Inc.
- Ticker
- MRNA
- Tx kind
- open_market_sale
- Tx date
- Aug 5, 2026
- Shares
- 147,473
- Price
- $56
- Value
- $8.3M
- Is 10b5 1
- Yes
- 27Exec saleAug 5, 2026
MRNA CEO Stephane Bancel sold $7.1M (10b5-1 plan)
Details
- Insider
- Stephane Bancel
- Company
- Moderna, Inc.
- Ticker
- MRNA
- Tx kind
- open_market_sale
- Tx date
- Aug 5, 2026
- Shares
- 124,838
- Price
- $57
- Value
- $7.1M
- Is 10b5 1
- Yes
- 68Exec buyMar 3, 2025
MRNA CEO Stephane Bancel bought $3.2M on the open market
Details
- Insider
- Stephane Bancel
- Company
- Moderna, Inc.
- Ticker
- MRNA
- Tx kind
- open_market_buy
- Tx date
- Mar 3, 2025
- Shares
- 102,821
- Price
- $31
- Value
- $3.2M
- Is 10b5 1
- No
- 64Exec buyMar 3, 2025
MRNA CEO Stephane Bancel bought $1.8M on the open market
Details
- Insider
- Stephane Bancel
- Company
- Moderna, Inc.
- Ticker
- MRNA
- Tx kind
- open_market_buy
- Tx date
- Mar 3, 2025
- Shares
- 57,493
- Price
- $32
- Value
- $1.8M
- Is 10b5 1
- No
- 50Insider overlapFeb 25, 2025
Rep. Robert P. Bresnahan, Jr. bought MRNA 6 days before its CEO bought $3.2M
Details
- Politician
- Robert P. Bresnahan, Jr.
- Ticker
- MRNA
- Asset
- Moderna, Inc. - Common Stock (MRNA)
- Tx type
- buy
- Tx date
- Feb 25, 2025
- Filing date
- Mar 27, 2025
- Amount low
- $1,001
- Amount high
- $15,000
- Amount mid
- $8,001
- Disclosed range
- $1,001 - $15,000
- Reporting lag days
- 30
- Is whale
- No
- Insider trade
- {"insider":{"slug":"stephane-bancel","name":"Stephane Bancel","title":"Chief Executive Officer","short_title":"CEO"},"company":"Moderna, Inc.","ticker":"MRNA","tx_kind":"open_market_buy","tx_date":"2025-03-03","shares":102821,"price":31.04,"value":3191563.84,"is_10b5_1":false}
- Days between
- -6
- Opposite side
- No
Transactions
Independent third-party platform; not affiliated with or endorsed by any member of Congress. Data sourced from publicly available filings and records. Portfolio, holdings, returns, and allocations are estimates and may differ from actual values. Informational and educational only; not investment advice. Shares, prices and post-transaction holdings are exactly as reported on SEC Form 4; the whale score is a model ranking of that filed activity.